Nathanael Kane1, Tahmineh Romero2, Silvia Diaz-Perez1, Matthew B Rettig3, Michael L Steinberg1, Amar U Kishan1,3, Dorthe Schaue1, Robert E Reiter3, Beatrice S Knudsen4, Nicholas G Nickols5,6,7. 1. Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 2. Statistic Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 3. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 4. Department of Pathology, University of Utah, Salt Lake City, UT, USA. 5. Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. nnickols@mednet.ucla.edu. 6. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. nnickols@mednet.ucla.edu. 7. Radiation Oncology Service, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. nnickols@mednet.ucla.edu.
Abstract
BACKGROUND: Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients. METHODS: Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy. RESULTS: Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.
BACKGROUND: Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients. METHODS: Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy. RESULTS: Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.
Authors: Joshua Saylor; Zhaoxuan Ma; Helen S Goodridge; Fangjin Huang; Anne E Cress; Stephen J Pandol; Stephen L Shiao; Adriana C Vidal; Lily Wu; Nicholas G Nickols; Arkadiusz Gertych; Beatrice S Knudsen Journal: Front Immunol Date: 2018-12-14 Impact factor: 7.561
Authors: Lin Lin; Nathanael Kane; Naoko Kobayashi; Evelyn A Kono; Joyce M Yamashiro; Nicholas G Nickols; Robert E Reiter Journal: Clin Cancer Res Date: 2020-11-20 Impact factor: 12.531
Authors: Neil R Parikh; Amar U Kishan; Nathanael Kane; Silvia Diaz-Perez; Ekambaram Ganapathy; Ramin Nazarian; Carol Felix; Colleen Mathis; Margaret Bradley; Ankush Sachdeva; Bashir Wyatt; Vince Basehart; Nazy Zomorodian; Lin Lin; Christopher R King; Patrick A Kupelian; Matthew B Rettig; Michael L Steinberg; Minsong Cao; Beatrice S Knudsen; David Elashoff; Dorthe Schaue; Robert E Reiter; Nicholas G Nickols Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-17 Impact factor: 7.038
Authors: Nicholas G Nickols; Ekambaram Ganapathy; Christine Nguyen; Nathanael Kane; Lin Lin; Silvia Diaz-Perez; Ramin Nazarian; Colleen Mathis; Care Felix; Vince Basehart; Nazy Zomorodian; Jae Kwak; Amar U Kishan; Christopher R King; Patrick A Kupelian; Matthew B Rettig; Michael L Steinberg; Minsong Cao; Beatrice S Knudsen; Fang-I Chu; Tahmineh Romero; David Elashoff; Robert E Reiter; Dörthe Schaue Journal: Prostate Cancer Prostatic Dis Date: 2020-07-09 Impact factor: 5.554